Concepedia

Michael W. Sill

MW

80

Publications

9.6K

Citations

40

H-Index

2005

Active since

Affiliations

Gynecologic Oncology Group(Current)

Roswell Park Comprehensive Cancer Center

University of Oklahoma

Memorial Sloan Kettering Cancer Center

University at Buffalo, State University of New York

Michael W. Sill is an author at Gynecologic Oncology Group specializing in medicine, obstetrics, and oncology.

ORCID

Top concepts

Publications per year

2005–2025

80

Publications

80

Improved Survival with Bevacizumab in Advanced Cervical Cancer

Krishnansu S. Tewari, Michael W. Sill, Harry J. Long et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text

Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

Robert A. Burger, Michael W. Sill, Bradley J. Monk et al. · Journal of Clinical Oncology · 2007 · 878 citations · Full text

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

Bradley J. Monk, Michael W. Sill, D. Scott McMeekin et al. · Journal of Clinical Oncology · 2009 · 681 citations · Full text

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson et al. · The Lancet · 2017 · 656 citations · Full text

, , +11

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Ramez N. Eskander, Michael W. Sill, Lindsey Beffa et al. · New England Journal of Medicine · 2023 · 626 citations · Full text

Rows per page

1–5 of 80